A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women

2014 ◽  
Vol 21 (3) ◽  
pp. 227-235 ◽  
Author(s):  
David F. Archer ◽  
Thomas Schmelter ◽  
Matthias Schaefers ◽  
Christoph Gerlinger ◽  
Kerstin Gude
Keyword(s):  
Effective Dose ◽  
Postmenopausal Women ◽  
Controlled Study ◽  
Vasomotor Symptoms ◽  
Double Blind ◽  
Double Blind Placebo ◽  
17Β Estradiol

A simple enzyme-linked immunosorbent assay of human osteocalcin

1994 ◽  
Vol 40 (7) ◽  
pp. 1258-1264 ◽  
Author(s):  
C Rosenquist ◽  
M Bonde ◽  
C Fledelius ◽  
P Qvist
Keyword(s):  
Postmenopausal Women ◽  
Polyclonal Antibodies ◽  
Premenopausal Women ◽  
Controlled Study ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Osteocalcin ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Early Postmenopausal Women ◽  
Log Linear

Abstract A heterologous ELISA for measurement of osteocalcin (bone Gla-protein) is described, involving biotinylated bovine osteocalcin and polyclonal antibodies. The log-linear range was 2.3-37.5 micrograms/L. Between-run (total) and within-run CVs (n = 10) were 5.7-6.4 and 5.9-6.1%, respectively; analytical recoveries ranged from 92% to 108%. Comparison of our method (x) with an RIA (y) yielded y = 1.10 x -0.01 microgram/L, Sylx = 1.4 micrograms/L, r = 0.958 (n = 167). Serum osteocalcin in healthy premenopausal women (n = 29) was 8.7 +/- 3.3 micrograms/L (mean +/- SD) and 11.8 +/- 4.5 micrograms/L in early-postmenopausal women (n = 24). The assay was evaluated in a double-blind placebo-controlled study of healthy early-postmenopausal women, treated for 12 months with either (a) estrogen valerate plus medroxyprogesterone acetate (n = 18), (b) 17 beta-estradiol and desogestrel (n = 22), or (c) placebo (n = 17). Serum osteocalcin decreased significantly (P < 0.001) with either therapy, but increased (P < 0.05) with placebo.

Sign in / Sign up

Export Citation Format

Share Document